These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 15907151)

  • 1. Effectiveness and cost of risperidone and olanzapine for schizophrenia: a systematic review.
    Hargreaves WA; Gibson PJ
    CNS Drugs; 2005; 19(5):393-410. PubMed ID: 15907151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
    Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
    Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacoeconomic evaluation of schizophrenia in Taiwan: model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated costs.
    Yang YK; Tarn YH; Wang TY; Liu CY; Laio YC; Chou YH; Lee SM; Chen CC
    Psychiatry Clin Neurosci; 2005 Aug; 59(4):385-94. PubMed ID: 16048443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacy cost evaluation of risperidone, olanzapine, and quetiapine for the treatment of schizophrenia in acute care inpatient settings.
    Mladsi DM; Grogg AL; Irish WD; Lopez RB; Degen K; Swann A; Nimsch CT
    Curr Med Res Opin; 2004 Dec; 20(12):1883-93. PubMed ID: 15701206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Olanzapine: an updated review of its use in the management of schizophrenia.
    Bhana N; Foster RH; Olney R; Plosker GL
    Drugs; 2001; 61(1):111-61. PubMed ID: 11217867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of co-morbidities with prescribing patterns and cost savings: olanzapine versus risperidone for schizophrenia.
    Yu W; Ren XS; Lee AF; Herz L; Huang YH; Kazis LE
    Pharmacoeconomics; 2006; 24(12):1233-48. PubMed ID: 17129077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decision analysis model evaluating the cost-effectiveness of risperidone, olanzapine and haloperidol in the treatment of schizophrenia.
    Bounthavong M; Okamoto MP
    J Eval Clin Pract; 2007 Jun; 13(3):453-60. PubMed ID: 17518814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes and costs of risperidone versus olanzapine in patients with chronic schizophrenia or schizoaffective disorders: a Markov model.
    Vera-Llonch M; Delea TE; Richardson E; Rupnow M; Grogg A; Oster G
    Value Health; 2004; 7(5):569-84. PubMed ID: 15367252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis.
    De Graeve D; Smet A; Mehnert A; Caleo S; Miadi-Fargier H; Mosqueda GJ; Lecompte D; Peuskens J
    Pharmacoeconomics; 2005; 23 Suppl 1():35-47. PubMed ID: 16416760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
    Krzystanek M; Krupka-Matuszczyk I
    Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing cost-effectiveness of drug interventions for schizophrenia.
    Magnus A; Carr V; Mihalopoulos C; Carter R; Vos T
    Aust N Z J Psychiatry; 2005; 39(1-2):44-54. PubMed ID: 15660705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risperidone compared with olanzapine in a naturalistic clinical study in Ireland: a cost analysis.
    Lucey JV; Libretto SE
    Ir J Med Sci; 2003; 172(4):195-201. PubMed ID: 15029989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risperidone compared with olanzapine in a naturalistic clinical study: a cost analysis.
    Taylor DM; Wright T; Libretto SE;
    J Clin Psychiatry; 2003 May; 64(5):589-97. PubMed ID: 12755664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a medicaid population.
    Gibson PJ; Damler R; Jackson EA; Wilder T; Ramsey JL
    Value Health; 2004; 7(1):22-35. PubMed ID: 14720128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost of antipsychotic polypharmacy in the treatment of schizophrenia.
    Zhu B; Ascher-Svanum H; Faries DE; Correll CU; Kane JM
    BMC Psychiatry; 2008 Apr; 8():19. PubMed ID: 18394168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.
    Dossenbach M; Pecenak J; Szulc A; Irimia V; Anders M; Logozar-Perkovic D; Peciukaitiene D; Kotler M; Smulevich AB; West TM; Lowry AJ; Treuer T
    J Clin Psychiatry; 2008 Dec; 69(12):1901-15. PubMed ID: 19012820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing the cost effectiveness of risperidone and olanzapine in the treatment of schizophrenia using the net-benefit regression approach.
    De Ridder A; De Graeve D
    Pharmacoeconomics; 2009; 27(1):69-80. PubMed ID: 19178125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A population-based cost-effectiveness analysis of olanzapine and risperidone among ambulatory patients with schizophrenia.
    Cooper D; Moisan J; Abdous B; Grégoire JP
    Can J Clin Pharmacol; 2008; 15(3):e385-97. PubMed ID: 18953083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Olanzapine versus risperidone in the treatment of schizophrenia : a comparison of costs among Texas Medicaid recipients.
    Rascati KL; Johnsrud MT; Crismon ML; Lage MJ; Barber BL
    Pharmacoeconomics; 2003; 21(10):683-97. PubMed ID: 12828491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comments on cost analysis of risperidone versus olanzapine.
    Duggal HS; Gandotra G
    J Clin Psychiatry; 2004 Jun; 65(6):879-80; author reply 880. PubMed ID: 15291670
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.